All Stories

  1. Prophylaxis for invasive fusariosis
  2. Tu1952 Serum Levels of 1,3-beta-D-Glucan Are Associated With Intestinal Inflammation in Crohn's Disease
  3. Fusariosis
  4. Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
  5. Diagnosis of Candidemia
  6. Epidemiology of Fusariosis
  7. Increased Incidence of Invasive Fusariosis with Cutaneous Portal of Entry, Brazil
  8. New serological markers in medical mycology: (1,3)-(-D-glucan and Aspergillus galactomannan
  9. Prevention of Infections in Patients with Hematological Malignancies
  10. Use of antifungal drugs in hematology
  11. Epidemiology of endemic systemic fungal infections in Latin America
  12. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment
  13. Management of Infectious Complications in Patients with Leukemia
  14. Mucocutaneous and Deeply Invasive Candidiasis
  15. Antibacterial, Antifungal, and Antiviral Prophylaxis in High-Risk Cancer and Stem Cell Transplant Population
  16. Emerging Fungal Infections
  17. D-index and Prediction of Infection
  18. Persistent Candidemia: Causes and Investigations
  19. Epidemiology of Opportunistic Fungal Infections in Latin America
  20. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis
  21. Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
  22. Infection in multiple myeloma
  23. Infections in Patients With Multiple Myeloma
  24. Fungal Infections in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation—Focus on Aspergillosis
  25. Low-Grade Lymphoma Following Intensive Treatment of Large-Cell Lymphoma
  26. Paracoccidioidomycosis
  27. Hyalohyphomycosis
  28. Invasive fungal infections in cancer patients
  29. Infecciones fúngicas emergentes
  30. Emerging Fungal Infections
  31. Multiple Myeloma
  32. Infections fongiques émergentes
  33. Optimising the Use of Non-invasive Tests: From Blood to Radiology
  34. When Primary Antifungal Therapy Fails
  35. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals
  36. Infecção em Mieloma Múltiplo
  37. Emerging Fungi
  38. Epidemiologia, tratamento e profilaxia das infecções na leucemia linfóide crônica
  39. Candidemia in Patients with Cancer: Are Persistent Neutropenia and Severity of Illness Score Still Relevant?
  40. Prothrombin 20210A and Oral Contraceptive Use as Risk Factors for Cerebral Venous Thrombosis
  41. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients
  42. Reply
  43. Cutaneous Infection by Fusarium Species in Healthy and Immunocompromised Hosts: Implications for Diagnosis and Management
  44. Emergence of resistant Candida in neutropenic patients
  45. Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease
  46. Resistant bacteria in stem cell transplant recipients
  47. Revisiting the Source of Candidemia: Skin or Gut?
  48. Can we decrease amphotericin nephrotoxicity?
  49. Emergence of black moulds in fungal disease: epidemiology and therapy
  50. INFECÇÕES EM TRANSPLANTE DE MEDULA ÓSSEA
  51. Resistance to Activated Protein C in Thrombophilic Patients in Rio de Janeiro
  52. Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients
  53. Faculty of 1000 evaluation for Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.
  54. Faculty of 1000 evaluation for Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis.
  55. Faculty of 1000 evaluation for Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).
  56. Faculty of 1000 evaluation for Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.
  57. Faculty of 1000 evaluation for Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis in Adult Patients with Invasive Fungal Infections.
  58. Faculty of 1000 evaluation for Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.
  59. Faculty of 1000 evaluation for Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.